Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS: We conclude that treprostinil treatment significantly improved exercise capacity, dyspnea and functional class. Several plasma proteins that might track disease were abnormal at baseline, and changes were associated with improved exercise capacity.
|
Authors | Jagdish Hiremath, Sadagopa Thanikachalam, Keyur Parikh, Somasundaram Shanmugasundaram, Sudhakar Bangera, Leland Shapiro, Gregory B Pott, Cindy L Vnencak-Jones, Carl Arneson, Michael Wade, R James White, TRUST Study Group |
Journal | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
(J Heart Lung Transplant)
Vol. 29
Issue 2
Pg. 137-49
(Feb 2010)
ISSN: 1557-3117 [Electronic] United States |
PMID | 20022264
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Biomarkers
- Epoprostenol
- treprostinil
|
Topics |
- Adolescent
- Adult
- Aged
- Antihypertensive Agents
(administration & dosage)
- Biomarkers
(blood)
- Double-Blind Method
- Epoprostenol
(administration & dosage, analogs & derivatives)
- Exercise
- Female
- Humans
- Hypertension, Pulmonary
(drug therapy)
- Infusions, Intravenous
- Male
- Middle Aged
- Physical Endurance
(drug effects)
- Severity of Illness Index
- Treatment Outcome
- Walking
|